The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Celgene; Istari Oncology; Orbus Therapeutics
Research Funding - Genentech/Roche (Inst); Orbus Therapeutics (Inst); Symphogen (Inst); Triphase Accelerator Corp (Inst)
Patents, Royalties, Other Intellectual Property - AU 2013347945 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CN 201380070749.7 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2015-544130 Div: 2017-084158 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, and a patent; PCT/US17/023148 - Combination Therapy for Cancer Using Oncolytic Poliovirus licensed to Istari and Stock options, ISTARI Oncology; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent
 
Dina Randazzo
Consulting or Advisory Role - Optune
Research Funding - Medicenna (Inst)
 
Vidyalakshmi Chandramohan
No Relationships to Disclose
 
Katherine B. Peters
Consulting or Advisory Role - Abbvie; Agios; Bayer; Boehringer Ingelheim; Eisai
Research Funding - Abbvie; Agios; BioMimetix; BioMimetix; Bristol-Myers Squibb; Novocure
 
Margaret O Johnson
No Relationships to Disclose
 
Stevie Threatt
No Relationships to Disclose
 
Chevelle A Bullock
No Relationships to Disclose
 
James Emmett Herndon
No Relationships to Disclose
 
Patrick Healy
No Relationships to Disclose
 
Eric S Lipp
No Relationships to Disclose
 
John H. Sampson
Stock and Other Ownership Interests - Annias Immunotherapeutics; ISTARI
Consulting or Advisory Role - Annias Immunotherapeutics; Insera Health; Medicenna
Patents, Royalties, Other Intellectual Property - Annias Immunotherapeutics - Equity, Licensed IP; Istari Oncology - Equity, Licensed IP; Neuronium - Equity, Optioned IP
 
Allan H. Friedman
No Relationships to Disclose
 
Henry S. Friedman
Leadership - Istari Oncology
Stock and Other Ownership Interests - Cancer Expert Now; Diverse Biotech; ISTARI Oncology
Consulting or Advisory Role - Cancer Expert Now
Patents, Royalties, Other Intellectual Property - Letters of Patent for Oncolytic Poliovirus for Human Tumors
 
David M. Ashley
Stock and Other Ownership Interests - Diverse Biotech
Consulting or Advisory Role - Istari Oncology, Inc.; Jackson Laboratory for Genomic Medicine
Patents, Royalties, Other Intellectual Property - Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/787,508 filed January 2, 2019 Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/620,577 filed January 23, 2018
Expert Testimony - Tanoury, Nauts, McKinney & Garbarino, PLLC
 
Darell D. Bigner
No Relationships to Disclose